Van ECK Associates Corp Cuts Position in Repligen Co. (NASDAQ:RGEN)

Van ECK Associates Corp cut its stake in Repligen Co. (NASDAQ:RGENFree Report) by 2.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,552 shares of the biotechnology company’s stock after selling 1,611 shares during the period. Van ECK Associates Corp owned about 0.10% of Repligen worth $8,675,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Oppenheimer Asset Management Inc. lifted its position in Repligen by 327.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 16,254 shares of the biotechnology company’s stock valued at $2,299,000 after acquiring an additional 12,453 shares during the last quarter. Atria Investments Inc purchased a new stake in shares of Repligen in the third quarter valued at about $1,046,000. Portside Wealth Group LLC purchased a new stake in shares of Repligen in the second quarter valued at about $4,008,000. Fortis Capital Management LLC purchased a new stake in shares of Repligen in the third quarter valued at about $1,479,000. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of Repligen by 130.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 11,500 shares of the biotechnology company’s stock valued at $1,829,000 after buying an additional 6,500 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Trading Up 0.5 %

Shares of RGEN opened at $205.00 on Friday. The firm’s 50-day moving average is $179.97 and its two-hundred day moving average is $165.76. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $208.16. The firm has a market capitalization of $11.45 billion, a P/E ratio of 100.99, a PEG ratio of 4.75 and a beta of 1.04.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on RGEN. Royal Bank of Canada reduced their target price on shares of Repligen from $207.00 to $200.00 and set an “outperform” rating for the company in a report on Wednesday, November 1st. KeyCorp cut their price target on shares of Repligen from $240.00 to $210.00 and set an “overweight” rating for the company in a report on Wednesday, November 1st. Benchmark cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Monday, December 4th. JPMorgan Chase & Co. increased their price target on shares of Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Finally, Stifel Nicolaus cut their price target on shares of Repligen from $200.00 to $165.00 and set a “buy” rating for the company in a report on Wednesday, November 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $191.50.

Get Our Latest Report on Repligen

Repligen Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.